The London Life Sciences team advised MiNA Therapeutics on its global research collaboration with Eli Lilly and Company (NYSE: LLY) to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform.
MiNA is a leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore normal function to patients' cells.
Under the terms of the agreement, MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic focus areas. Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration. MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration.
The Goodwin team was led by Malcolm Bates.
For more details, please read the press release and coverage in The Times, BioSpace, and Pharmaceutical Technology.